Helen L. and Martin S. Kimmel Center for Biology and Medicine, Skirball Institute of Biomolecular Medicine, NYU Medical School, New York, NY 10016, USA.
Cell Rep. 2012 Sep 27;2(3):497-502. doi: 10.1016/j.celrep.2012.08.004. Epub 2012 Aug 30.
Amyotrophic lateral sclerosis (ALS) is a devastating disease that progresses from detachment of motor nerve terminals to complete muscle paralysis and lethal respiratory failure within 5 years of diagnosis. Genetic studies have linked mutations in several genes to ALS, and mice bearing mutations in SOD1 recapitulate hallmark features of the disease. We investigated whether disease symptoms can be ameliorated by co-opting the retrograde signaling pathway that promotes attachment of nerve terminals to muscle. We crossed SOD1G93A mice with transgenic mice that express MuSK, a receptor tyrosine kinase that is required for retrograde signaling, and we used histological and behavioral assays to assess motor innervation and behavior. A 3-fold increase in MuSK expression delayed the onset and reduced the extent of muscle denervation, improving motor function for more than a month without altering survival. These findings suggest that increasing MuSK activity by pharmacological means has the potential to improve motor function in ALS.
肌萎缩侧索硬化症(ALS)是一种毁灭性疾病,从运动神经末梢的分离到完全肌肉瘫痪和致命性呼吸衰竭,在诊断后的 5 年内进展。遗传研究已经将几个基因的突变与 ALS 联系起来,并且携带 SOD1 突变的小鼠再现了该疾病的标志性特征。我们研究了通过利用促进神经末梢附着到肌肉的逆行信号通路是否可以改善疾病症状。我们将 SOD1G93A 小鼠与表达 MuSK 的转基因小鼠杂交,MuSK 是一种受体酪氨酸激酶,是逆行信号所必需的,我们使用组织学和行为学检测来评估运动神经支配和行为。MuSK 表达增加 3 倍可延迟发病并减少肌肉去神经支配的程度,改善运动功能超过一个月而不改变生存。这些发现表明,通过药理学手段增加 MuSK 活性有可能改善 ALS 的运动功能。